Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) Equity Average (2016 - 2026)

Ekso Bionics Holdings has reported Equity Average over the past 13 years, most recently at $9.4 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 32.17% to $9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.4 million, a 32.17% decrease, with the full-year FY2025 number at $10.9 million, down 14.14% from a year prior.
  • Equity Average reached $9.4 million in Q4 2025 per EKSO's latest filing, down from $10.3 million in the prior quarter.
  • The five-year high for Equity Average was $40.5 million in Q2 2021, with the low at $9.4 million in Q4 2025.
  • The 5-year median for Equity Average is $18.0 million (2023), against an average of $21.9 million.
  • Peak YoY movement for Equity Average: skyrocketed 1459.06% in 2021, then crashed 48.46% in 2023.
  • Tracing EKSO's Equity Average over 5 years: stood at $38.1 million in 2021, then dropped by 29.14% to $27.0 million in 2022, then crashed by 48.46% to $13.9 million in 2023, then dropped by 1.03% to $13.8 million in 2024, then crashed by 32.17% to $9.4 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $9.4 million, $10.3 million, and $11.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.